AU2009324495B2 - Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles - Google Patents

Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles Download PDF

Info

Publication number
AU2009324495B2
AU2009324495B2 AU2009324495A AU2009324495A AU2009324495B2 AU 2009324495 B2 AU2009324495 B2 AU 2009324495B2 AU 2009324495 A AU2009324495 A AU 2009324495A AU 2009324495 A AU2009324495 A AU 2009324495A AU 2009324495 B2 AU2009324495 B2 AU 2009324495B2
Authority
AU
Australia
Prior art keywords
alkyl
pharmaceutically acceptable
hydrogen
multiple sclerosis
arylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009324495A
Other languages
English (en)
Other versions
AU2009324495A1 (en
Inventor
Spyros Deftereos
Andreas Persidis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovista Inc
Original Assignee
Biovista Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovista Inc filed Critical Biovista Inc
Publication of AU2009324495A1 publication Critical patent/AU2009324495A1/en
Application granted granted Critical
Publication of AU2009324495B2 publication Critical patent/AU2009324495B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2009324495A 2008-12-11 2009-12-11 Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles Ceased AU2009324495B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12157408P 2008-12-11 2008-12-11
US61/121,574 2008-12-11
US23323509P 2009-08-12 2009-08-12
US61/233,235 2009-08-12
PCT/US2009/067673 WO2010068867A1 (en) 2008-12-11 2009-12-11 Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles

Publications (2)

Publication Number Publication Date
AU2009324495A1 AU2009324495A1 (en) 2011-07-28
AU2009324495B2 true AU2009324495B2 (en) 2015-12-24

Family

ID=42243090

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009324495A Ceased AU2009324495B2 (en) 2008-12-11 2009-12-11 Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles

Country Status (9)

Country Link
US (1) US20110268699A1 (https=)
EP (1) EP2375900B1 (https=)
JP (1) JP2012512165A (https=)
CN (1) CN102395275A (https=)
AU (1) AU2009324495B2 (https=)
BR (1) BRPI0922871A2 (https=)
CA (1) CA2747235C (https=)
IL (1) IL213476A0 (https=)
WO (1) WO2010068867A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010031054A1 (en) 2008-09-15 2010-03-18 Biovista, Inc. Compositions and methods for treating epilepsy
CA2777827C (en) 2009-10-30 2020-08-18 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
AU2012249920B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Disorders implicating PUFA oxidation
AU2012249917B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Neurodegenerative disorders and muscle diseases implicating PUFAs
EP3689342A1 (en) 2011-04-26 2020-08-05 Retrotope, Inc. Oxidative retinal diseases
AU2012249918B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Impaired energy processing disorders and mitochondrial deficiency
WO2013130422A1 (en) * 2012-02-27 2013-09-06 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
EA201591507A1 (ru) * 2013-02-15 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Лечение рассеянного склероза лахинимодом
KR101521807B1 (ko) * 2014-01-20 2015-05-20 한국전자통신연구원 데이터 전송 제어 장치 및 그 방법
HRP20241165T1 (hr) * 2014-05-09 2024-11-22 Tecnimede Sociedade Tecnico-Medicinal S.A. Mandelatne soli enantiomera pirlindola za upotrebu u medicini
CA3005983A1 (en) 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HUE071047T2 (hu) 2016-08-31 2025-07-28 Mapi Pharma Ltd Glatiramer-acetátot tartalmazó depórendszerek
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
EP3520803A1 (en) * 2018-01-31 2019-08-07 Zarodex Therapeutics Limited Novel uses
CA3172351A1 (en) 2020-02-21 2021-08-26 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959470A (en) * 1972-11-28 1976-05-25 Mikhail Davidovich Mashkovsky Psychotropic medicinal preparation
WO2006048242A2 (en) * 2004-11-02 2006-05-11 Switch Biotech Ag Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US20070270429A1 (en) * 2003-05-06 2007-11-22 Shiro Shibayama Function Inhibitor of Effector Cell
RU2281085C2 (ru) * 2004-05-25 2006-08-10 Закрытое акционерное общество "Мастерлек" Антидепрессивные лекарственные средства для парентерального применения на основе сульфонатных солей пирлиндола
CA2617102A1 (en) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
JP2010528016A (ja) * 2007-05-25 2010-08-19 メディベーション ニューロロジー， インコーポレイテッド 細胞を刺激するための方法および組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959470A (en) * 1972-11-28 1976-05-25 Mikhail Davidovich Mashkovsky Psychotropic medicinal preparation
WO2006048242A2 (en) * 2004-11-02 2006-05-11 Switch Biotech Ag Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOLAND A et al., British Journal of Pharmacology, vol. 135, no. 3, February 2002, pages 713-720 *

Also Published As

Publication number Publication date
EP2375900A4 (en) 2012-05-02
EP2375900A1 (en) 2011-10-19
EP2375900B1 (en) 2016-03-02
US20110268699A1 (en) 2011-11-03
CA2747235C (en) 2021-02-09
WO2010068867A1 (en) 2010-06-17
AU2009324495A1 (en) 2011-07-28
BRPI0922871A2 (pt) 2016-11-16
CN102395275A (zh) 2012-03-28
IL213476A0 (en) 2011-07-31
CA2747235A1 (en) 2010-06-17
JP2012512165A (ja) 2012-05-31

Similar Documents

Publication Publication Date Title
AU2009324495B2 (en) Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
US20110195049A1 (en) Compositions and methods for treating multiple sclerosis
JP5490292B2 (ja) 医学的状態を治療するための方法、組成物、およびキット
JP2007332156A (ja) 性的不能の治療に有効な組合せ
US20130225603A1 (en) Mdm2 inhibitors for treatment of ocular conditions
US8735397B2 (en) Method for treating schizophrenia and related diseases
JP2012502915A (ja) てんかんを治療する組成物及び方法
KR20180094965A (ko) 위장 괄약근 기능장애의 치료를 위한 sGC 자극제의 용도
US10098875B2 (en) Method of treatment for mental disorders
JPWO2005094885A1 (ja) 慢性筋骨格痛を呈する疾患の予防および／または治療剤
AU3724400A (en) Methods and compositions for treating erectile dysfunction
US10172854B2 (en) Compositions and methods for treating mitochondrial diseases
JP2004508272A (ja) アセチルコリンエンハンサー
JPWO2004043491A1 (ja) 脊柱管狭窄症治療剤
CN1247578C (zh) 含有2－芳基－8－氧化二氢嘌呤衍生物作为活性成分的痴呆症治疗剂
HK1128593B (en) A composition suitable for ophthalmic administration
WO2019023318A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS USING PYRIDOSTIGMINE AND AN ANTAGONIST OF NK-1 FOR TREATING SEVERE MYASTHENIA
HK1032911A (en) Combination effective for the treatment of impotence
WO2001030388A1 (en) Tension-relieving agents for ciliary muscle

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired